

## Publications

---

### Theses

1. **Vitetta L.** Biogenesis of mitochondria: physical mapping studies of mitochondrial DNA and RNA through molecular hybridizations. BSc Honors Report, Monash University, Pp 1-58, 1981.
2. **Vitetta L.** Gallstone composition and dissolution: an epidemiological and aetiological study. Vol 1 and 2: Pp 1-475. PhD Thesis, University of Melbourne, Dissertation Abstracts International, 47(6), 1986. Ann Arbor, Michigan, USA.

### Chapter in Books [x10]

---

1. Kune GA, **Vitetta L.** Colorectal Cancer. Chapter 27, Pages: 787-798. In: Testing, Predicting and Interpreting Carcinogenicity. KT Kitchin (ed), Marcel Dekker, NY, 1999. ISBN: 0824798937
2. **Vitetta L.** Nutritional Factors Including Anti-Oxidants in Dementia and Anti-Aging. R Goldman and R Klatz Eds. In: Anti-Aging Therapeutics 2003; Volume VI, Ch 26, Pp 243-248. [An official educational work published by A4M publications] ISBN: 0-9668937-5-1 (print and CD ROM)
3. **Vitetta L**, Anton B, Cortizo F, Sali A. Mind Body Medicine: Stress and its impact on Overall Health and Longevity. In: Reversal of Aging, Myth and Reality: Beyond the Man-Made Barriers. Part VI. Replacement Therapies of a Failing Body: Clinical Evidence of Restorative Medicine: Annals New York Academy of Sciences Volume 1057; 2005; Pp 492-505.
4. Anton B, **Vitetta L**, Cortizo F, Sali A. Can We Delay Aging? The Biology and Science of Aging. In: Reversal of Aging, Myth and Reality: Beyond the Man-Made Barriers. Part VII. Striving for Health—Anti-aging Medicine and Its Presence in the World: The Witnesses and Pioneers of a Rapidly Changing and Aging Western Population: Annals New York Academy of Sciences Volume 1057;2005;Pp525-535.
5. **Vitetta L**, Ciccutini F, Sali A. Alternative Therapies for Musculoskeletal Conditions. In: Best Practice and Research in Clinical Rheumatology. Brooks P, Conaghan, P. eds. Elsevier Science Ltd.
6. **Vitetta L**, Sali A. Mind Body Medicine: The Key to Health and Longevity. Chapter in Book In: Mind Body and Relaxation Research Focus. Nova Press Scientific Publications. De Luca BD, ed., ISBN-10: 1600218199 ISBN-13: 978-1600218194.
7. Hoffman T, Bennett JW, Elkins MR, Lockwood C, Morgan A, Sanders S, Spencer A, **Vitetta L**, Wright C. Questions About the Effects of Interventions: Examples of Appraisals from Different Health Professions. Chapter in Book In: Evidence-Based Practice Across the Health Professions. Churchill Livingstone Publications. Eds. Hoffman T, Bennett S, Del Mar C, Ch5; 96-127. 2009. ISBN: 978-0-7295-3902-9.
8. Sali A, **Vitetta L.** Aging. In: General Practice: The Integrative Approach. Elsevier Ltd. Eds Phelps K., Hassad C. 2010; Ch 58 Pp841-857. ISBN: 9780729538046.

### Solicited book chapters from Springer, Basel AG.

9. **Vitetta L**, Hall S, Palacios T Coulson S. Pp 1-34. Gastrointestinal Tract Commensal Bacteria and Probiotics: Influence on End-Organ Physiology. In: Progress in Drug Research Novel Natural Products: Therapeutic Effects in Pain, Arthritis And Gastro-Intestinal Diseases [Editors: KD Rainsford, MC Powanda and MW Whitehouse] Publisher: Springer Basel AG. 2015. ISBN 978-3-0348-0926-9
10. Coulson S, Palacios T, **Vitetta L.** Pp 91-132. *Perna canaliculus* (Green Lipped Mussel): Bioactive Components and Therapeutic Evaluation for Chronic Health Conditions. In: Progress in Drug Research Novel Natural Products: Therapeutic Effects in Pain, Arthritis and Gastro-Intestinal Diseases [Editors: KD Rainsford, MC Powanda and MW Whitehouse] Publisher: Springer Basel AG. 2015. ISBN 978-3-0348-0926-9

---

### Solicited Text-Book [x1]

1. Kotsirilos V, **Vitetta L**, Sali A. A guide to evidence based integrative and complementary medicine. Eds. Kotsirilos V, Vitetta L, Sali A. Elsevier 2010, p1-956. Sydney, Australia. ISBN: 9780729539081.

### Commercial Requests and Consultancy Reports [x6]

---

1. **Vitetta L**, Paspaliaris B, Johnson M, Sali A. Cigarrest – a herbal tonic for cigarette and smoking cessation. Kepper Holdings 2001.
2. **Vitetta L**, Johnson M, Sali A. Contact Thermography Biological Therapies 2002
3. **Vitetta L**, Paspaliaris B, Johnson M, Sali A. The integrated inpatient management program for people with cancer: the scientific evidence and methodology to be employed 2002.
4. **Vitetta L**, Paspaliaris B, Johnson M, Cortizo F, Sali A. Body Enhancer: Product by Zenith Corporation (NZ) – The Scientific Evidence Part I 2002.
5. **Vitetta L**, Cortizo F, Sali A. Body Enhancer: Product by Zenith Corporation Ltd (NZ). The Scientific and Clinical Evidence: Part II. 2003
6. **Vitetta L**, Cortizo F, Sali A. Body Enhancer: Product by Zenith Corporation Ltd (NZ). Assessment of Clinical Trial Data. Part III. 2004.

### Literature Reviews – Funded / Solicited [x10]

---

1. Kissane DW, White K, Cooper K, **Vitetta L.** The Psychosocial impact in the areas of body image and sexuality for women with breast cancer. Publication for NHMRC National Breast Cancer Center Australia 2003. ISBN Print: 1 876319 78 X

2. **Vitetta L**, Gersh W, Johnson M, Mrazek L, Sali A. A National Needs Assessment of Parents of Children/Adolescents with Inflammatory Bowel Disease: Crohns Disease and Ulcerative Colitis. Publication for Australian Crohns and Colitis Association 2001
3. **Vitetta L**, Johnson M, Reavley N, Sali A. Psychosocial support of cancer patients. Publication for Federal Department of Veterans Health 2002.
4. **Vitetta L**, Coulson S, Beck S. Survey of Known Probiotics [Species / Strains] and Prebiotics with a Potential Health Benefit and Immunogenic Effects. Parmalat Review. February 2010.
5. **Vitetta L**, Beck SL, Coulson S, Trabi M. Black Cohosh [known as both *Actaea racemosa L.* and *Cimicifuga racemosa L.*]: Scientific Evaluation for Suspected Liver Toxicity. 2011. Part I. Swisse Multivitamins Pty Ltd
6. Trabi M, **Vitetta L**. Analysis of Women's Ultivite Preparations and *Cimifuga Racemosa* extracts. 2011. Part II. Swisse Multivitamins Pty Ltd
7. **Vitetta L**. Circulating tumour cells in clinical practice – is there scientific plausible evidence for analytical testing? 2011.
8. **Vitetta L**. Scientific literature review [with additional provision of UQ research laboratory / clinical data pertinent to the review], of the published scientific laboratory and clinical evidence for the use of IV ascorbate [Vitamin C] in the therapeutic treatment of cancer. 2011.
9. **Vitetta L**, Coulson S, Rao A, Steels E. Swisse Vitamins Pty Ltd Products: Scientific / Clinical Evidence and Allowable Claims – A Review. Part I, II and III. 2012.
10. **Vitetta L**. Independent assessment of probiotic systematic reviews for Parmalat Australia. 2019.

---

#### Refereed Journal Articles [161] – Invited Editorials [x28] – Commentaries / Correspondence [x21]

---

1. **Vitetta L**, Stubbs A, Purser S, Millar K, Sali A. Limy "milky" bile: without apparent gall-bladder obstruction by a gallstone. Aust NZ J Surg 1987; 57:405-408.
2. **Vitetta L**, Sali A, Chou ST, Fleming H, Little P, Elzarka A. Gallstones at autopsy and cholecystectomy: a comparative study. Aust NZ J Surg 1988; 58:561-568.
3. Kune GA, Kune S, Watson LF, Pierce RJ, Field B, **Vitetta L**. Serum levels of beta-carotene, vitamin A, and zinc in male lung cancer cases and controls. Nutr Cancer 1989; 12:169-176.
4. **Vitetta L**, Sali A, Moritz V, Shaw A, Carson P, Little P, Elzarka A. Bacteria and gallstone nucleation. Aust NZ J Surg 1989; 59:571-577.
5. Sali A, Oats JN, Acton CM, Elzarka A, **Vitetta L**. Effect of pregnancy on gallstone formation. Aust NZ J Obstet Gynaecol 1989; 29:386-389.
6. Gya D, Sali A, **Vitetta L**, Eu P, Arkles B. Limy bile cholecystitis: an in vitro study and a case report. Aust NZ J Surg 1990; 60:998-1000.
7. Sali A, **Vitetta L**. Gallstone decalcification and dissolution using chenodeoxycholate and citrate. HBP Surg 1990; 3:59-65.
11. **Vitetta L**, Sali A, Little P, Nayman J, Elzarka A. Primary "brown pigment" bile duct stones. HBP Surg 1991; 4:209-222.
12. Kune GA, Kune S, **Vitetta L**, Watson LF. Smoking and colorectal cancer risk: data from the Melbourne colorectal cancer study and brief review of literature. Int J Cancer 1992; 50:369-372.
13. Kune GA, **Vitetta L**. Alcohol consumption and the etiology of colorectal cancer: a review of the scientific evidence from 1957 to 1991. Nutr Cancer 1992; 18:97-111.
14. Kune GA, Bannerman S, Field B, Watson LF, Cleland H, Merenstein D, **Vitetta L**. Diet, alcohol, smoking, serum beta-carotene, and vitamin A in male nonmelanocytic skin cancer patients and controls. Nutr Cancer 1992;18:237-244.
15. **Vitetta L**, Sali A. Primary bile duct stones and bacterial activity. HBP Surg 1992; 6:23-33.
16. Kune GA, Kune S, Filed B, Watson LF, Cleland H, Merenstein D, **Vitetta L**. Oral and pharyngeal cancer, diet, smoking, alcohol, and serum vitamin A and beta-carotene levels: a case-control study in men. Nutr Cancer 1993; 20:61-70.
17. Kune GA, **Vitetta L**. Smoking and tobacco as an etiologic factor in gastric carcinoma. Gastrointestinal Cancer 1995;1:33-38.
18. Kune GA, **Vitetta L**. The causes of colorectal adenomas: the key to the control of colorectal cancer. J Royal Soc Med 1995; 88:625-628.
19. Kissane D, Clark D, Ikin J, Bloch S, Smith CS, **Vitetta L**, McKenzie DP. A cross-sectional survey of psychological morbidity and quality of life in Australian women with early stage breast cancer. Med J Aust 1998; 169(4):192-196.
20. **Vitetta L**, Kenner D. Another step for "electronics kind" eBMJ 6 November 1999.
21. Sali A, **Vitetta L**. Nutrition: Essence of a Healthy Life eBMJ 30 November 1999.
22. **Vitetta L**, Kenner D, Kissane D. The design and implementation of a computerized database for the efficient delivery of palliative care: with a brief review of the literature. Progress in Palliative Care 1999; 1:56-63.
23. **Vitetta L**, Sali A. Citrate: a component of bile and calcium chelator in gallbladder disease. J Nutr and Environ Med 1999; 9(3):199-207.
24. Sali A, **Vitetta L**. Complete Medicine—an integrative approach to health care. J Veteran's Health Aust 1999;68:32-33.
25. **Vitetta L**, Sali A. Tobacco on the shelf eBMJ 9 August 2000.
26. **Vitetta L**, Sali A, Reavley N, Sali A. What about nutrition and gestational diabetes. eBMJ 7 September 2000.
27. **Vitetta L**, Sali A, Reavley N, Sali A. A further thought to consider Re: smoking nutrition and gestational diabetes eBMJ 12 September 2000.
28. **Vitetta L**, Sali A, Little P, Mrazek L. Gallstones and Gallbladder Carcinoma. Aust NZ J Surg 2000;70:667-673.
29. **Vitetta L**, Kenner D Sali A. Bacterial Infections in terminally ill hospice patients. J Pain and Symptom Manag 2000; 20:326-334.

30. **Vitetta L**, Best S, Sali A. Single and multiple cholesterol gallstones and the influence of bacteria. *Medical Hypothesis* 2000; 55(6):502-506.
31. Glas R, Reavley N, Mrazek L, **Vitetta L**, Sali A. Psychosocial Interventions and cancer patients: psychological and immune responses may depend on cancer type. *Medical Hypothesis* 2001; 56(4):480-482.
32. **Vitetta L**, Kenner D, Kissane D, Sali A. Clinical outcomes in terminally ill patients admitted to hospice care: diagnostic and therapeutic interventions. *Journal of Palliative Care* 2001; Summer 17(2):69-77.
33. Ellis KA, Stough C, **Vitetta L**, Heinrich K, Nathan PJ. An investigation into the acute nootropic effects of hypericum perforatum L. (St John's Wort) in healthy human volunteers. *Behaviv Pharmacol* 2001;12:173-82.
34. Timoshanko A, Stough C, **Vitetta L**, Nathan PJ. A preliminary investigation on the acute pharmacodynamic effects of hypericum on cognitive and psychomotor performance. *Behavioural Pharmacol* 2001;12(8):635-640.
35. **Vitetta L**, Sali A, Reavley N. Does drinking carrot juice affect cancer of the prostate? *Med J Aust* 2001 175(1):52-3
36. **Vitetta L**, Sali A, Reavley N. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? *Med J Aust* 2001 175(8):447-448.
37. **Vitetta L**, Mrazek L, Sali A. A delay in the onset of obesity? *eBMJ* 5 December 2001.
38. **Vitetta L**, Sali A. Smoking cessation a difficult proposition: not without hope *eBMJ* 12 January 2002
39. **Vitetta L**, Sali A, Paspaliaris B, Reavley N. Mega – dose vitamin C in the treatment of the common cold: randomized controlled trial *Med J Aust* 2002 176(5):298-299.
40. **Vitetta L**, Kenner D, Sali A. As to the intention to hasten death of the terminally ill. *Med J Aust* 2002; 177(1):166-167.
41. **Vitetta L**, Barbaro C, Sali A. Vitamins Health and Scientific Evidence *eBMJ* 30 July 2002
42. **Vitetta L**, Thomsen M, Sali A. Black Cohosh and other herbal remedies associated with acute hepatitis. *Med J Aust* 2003; 178(8): 411-412.
43. Thomsen M, **Vitetta L**, Schmidt M, Sali A. Fatal fulminant hepatic failure induced by a natural therapy containing kava. *Med J Aust*. 2004; 180(4):198-9
44. Thomsen M, **Vitetta L**, Schmidt M, Sali A. Acute liver failure associated with the use of herbal preparations containing black cohosh. *Med J Aust* 2004; 180(11): 598-599.
45. Thomsen M, Schmidt M, **Vitetta L**, Sali A. Do herbs increase the risk of herb-drug interactions for patients with arthritis? *Ann Rheum Dis*. 2005; 64(10):1527.
46. Sali A, **Vitetta L**. Research in Complementary and Alternative Medicine. *Australasian Journal of Integrative Medicine* 2001;1(1): 59-61.
47. **Vitetta L**. Sali A. Integrative Medicine – A New Era with Global Implications for Health and Disease Prevention. *South African Journal of Natural Medicine* 2002;6:16-17.
48. Sali A, **Vitetta L**. Integrative Medicine– Keeping up with the evidence. *Journal Complementary Medicine* 2003; 2(6):36-41.
49. Sali A, **Vitetta L**. Nutritional Supplements and Cardiovascular Disease. *Heart Lung and Circulation Journal* 2004; 13(4):363-366.
50. **Vitetta L**, Sali A. Dementia. *Journal of Complementary Medicine* 2004; 3(1):14-19
51. Cortizo F, **Vitetta L** Functional Foods–Apples and Oats. *Journal of Complementary Medicine* 2004; 3(2):61.
52. Cortizo F, **Vitetta L**. Functional Foods–Soya and Flaxseed. *Journal of Complementary Medicine* 2004; 3(3):50-51.
53. Cortizo F, **Vitetta L**. Functional Foods–Broccoli and Cranberry. *Journal of Complementary Medicine* 2004; 3(4):65-66.
54. **Vitetta L**, Sali A. Placebo myth or reality–its role in clinical trials. *Journal of Complementary Medicine* 2004; 3(6):57-58.
55. Cortizo F, **Vitetta L**. Functional Foods–Teas. *Journal of Complementary Medicine* 2004; 3(6):79-80.
56. Di Vincenzo, **Vitetta L**, Ng F, Sali A. Nutritional and Lifestyle Factors influencing the progression and development of NIDDM in lean adult Vietnamese. *Journal of the Australasian Integrative Medicine Association* 2004; 23:25-30.
57. **Vitetta L**, Sali H, Burke J, Mrazek L, Cortizo F, Sali A. The live blood analysis technique. *Journal of the Australasian Integrative Medicine Association* 2005; 24:16-20.
58. Wang Y, Prentice LF, **Vitetta L**, Wluka AE, Cicuttini FM. Nutrition and dietary supplements and osteoarthritis. *Alternative Medicine Review Journal* 2004; 9(3):275-96.
59. Ellis JR, Ellis KA, Bartholomeuz CF, Harrison BJ, Wesnes KA, Erskine FF, **Vitetta L**, Nathan PJ. Muscarinic and Nicotinic Receptors Synergistically Modulate Working Memory and Attention in Humans. *International Journal of Neuropsychopharmacology* 2005; 9:1-15.
60. **Vitetta L**, Cortizo F, Sali A. Probiotics and Prebiotics in Health: an emerging new modality in biotherapeutics. *Journal of the Australasian Integrative Medicine Association* 2005; 25:18-22.
- 61.
62. **Vitetta L**, Kenner D, Sali A. Sedation and Analgesia Prescribing Patterns by Physicians in Terminally Ill Patients at the End of Life. *Am J Hosp Palliat Care* 2005; 22(6):465-73.
63. Wang Y, Cicuttini FM, **Vitetta L**, Wluka AE. What effect do dietary antioxidants have on the symptoms and structural progression of knee osteoarthritis over 2 years? *Clin Exp Rheumatol* 2006; 24(2):213-4.
64. **Vitetta L**, Sali A. Complementary Medicine Series: What is the evidence. Colorectal cancer and CHF - reviewing the evidence for complementary medicine. *Aust Fam Physician*. 2006; 35(5):339.
65. **Vitetta L**, Sali A. Complementary Medicine Series: What is the evidence. Treatments for damaged skin. *Aust Fam Physician* 2006; 35(7):501-2.
66. **Vitetta L**, Sali A. Complementary Medicine Series: What is the evidence. Complementary and Alternative Medicine and Palliative Care. *Aust Fam Physician* 2006; 35(10):783.

67. **Vitetta L.** Invited Commentary – Psychoneuroimmunology and occupational therapy for inflammatory disorders. *Intern J Ther Rehabil* 2006;13(11):510.
68. **Vitetta L, Sali A.** Omega-3 Fatty Acids PUFA - A Review PART I. *Journal of Complementary Medicine* 2006; 5(6):52-59.
69. Linnane AW, Kios M, **Vitetta L.** The Essential Roles of Superoxide Radical and Nitric Oxide Formation for Healthy Aging. *Mitochondrion* 2007; 7(1-2):1-5.
70. **Vitetta L, Sali A.** Complementary Medicine Series: What is the evidence. *Complementary and Alternative Medicine. Integrative medicine in gynaecological cancers. Aust Fam Physician.* 2007;36(3):135-6.
71. **Vitetta L, Sali A.** Omega-3 Fatty Acids PUFA - A Review PART II. *Journal of Complementary Medicine* 2007; 6:48-52.
72. Linnane AW, Kios M, **Vitetta L.** Healthy Aging: Regulation of the Metabolome by Cellular Redox Modulation and Prooxidant Signaling Systems. The Essential Roles of Superoxide Anion and Nitric Oxide. *Biogerontology* 2007;8:445-67.
73. Linnane AW, Kios M, **Vitetta L.** Coenzyme Q10 - Its role as a Prooxidant in the Formation of Superoxide Anion / Hydrogen Peroxide and the Regulation of the Metabolome. *Mitochondrion.* 2007; Suppl 1:S51-61.
74. **Vitetta L, Anton B.** Lifestyle and Nutrition, Caloric Restriction, Mitochondrial Health and Hormones: Scientific Interventions for Anti-Aging. *J Clinical Interventions in Aging* 2007;2(4):537-543.
75. Sali A, **Vitetta L.** Complementary Medicine Series: What is the evidence. *Complementary and Alternative Medicine and Arrhythmia. Austr Fam Physician* 2007;36(7):527-8.
76. Sali A, **Vitetta L** Peppermint and the gut. *Medicine Today* 2007;8(5):67-69.
77. **Vitetta L, Sali A.** Palliative Care. Nutritional Approaches. *J Compl Med* 2007; 6(4):16-26.
78. **Vitetta L. Sali A.** Life Stressors: Nutritional choices and obesity. *Journal Australasian Integrative Medicine Association* 2007; 12(3):8-13.
79. Sali A, **Vitetta L.** Integrative Medicine: In the Mix. *Australian Doctor* 2007; 20 April:39-40.
80. Sali A, **Vitetta L.** Therapy Update, Integrative Medicine: Management of Coronary Artery Disease. *Australian Doctor* 2007; 15 June: 39-43.
81. Sali A, **Vitetta L.** Therapy Update, Integrative Medicine: Management of Prostate Cancer. *Australian Doctor* 2007; 21 September: 35-36.
82. Sali A, **Vitetta L.** Therapy Update, Integrative Medicine: Tackling Osteoarthritis. *Australian Doctor* 2007; 23 November:41-45.
83. Sali A, **Vitetta L.** Therapy Update, Integrative Medicine: Diabetes under assault. *Australian Doctor* 2008; 4 April: 39-41.
84. Sali A, **Vitetta L.** Therapy Update, Integrative Medicine: Infertile. *Australian Doctor* 2008; 29 August: 38.
85. Sali A, **Vitetta L.** Care of the Cancer Patient by the General Practitioner (GP). *J Complementary Medicine* 2008; 7(2):28-29.
86. **Vitetta L.** Oxidative Stress and Antioxidants. *J Complementary Medicine* 2008;7(2):22- 25.
87. **Vitetta L, Sali A.** Probiotics, Prebiotics and Gastrointestinal Health. *Medicine Today* 2008;9:65-70.
88. **Vitetta L, Ciccutini F, Sali A.** Alternative therapies for musculoskeletal conditions, *Best Practice and Research Clinical Rheumatology* 2008; 22(3):499-522.
89. Pipingas A, Silberstein RB, **Vitetta L, Van Rooy C, Harris EV, Young JM, Frampton CM, Sali A, Nastase J.** Improved cognitive performance after dietary supplementation with a *Pinus radiata* bark extract formulation. *Phytother Res* 2008;22(9):1168-74.
90. Bartholomeusz CF, Wesnes KA, Kulkarni J, **Vitetta L, Croft RJ, Nathan PJ.** Estradiol Treatment and its Interaction with the Cholinergic System: Effects on Cognitive Function in Healthy Young Women. *Horm Behav* 2008;54:684-93.
91. Zhang AL, Story DF, Lin V, **Vitetta L, Xue CC.** A population survey on the use of 24 common medicinal herbs in Australia. *Pharmacoepidemiol Drug Saf* 2008;17(10):1006-13.
92. Kaur S, Mitchell G, **Vitetta L, Roberts MS.** Interventions that can reduce inappropriate prescribing in the elderly: a systematic review. *Drugs Aging* 2009;26(12):1013-28.
93. **Vitetta L, Sali A, Coulson S, Gray B.** Integrative management of type 2 diabetes mellitus. *JAIMA* 2010;15(2):6-13.
94. Steels E, Rao A, **Vitetta L.** Physiological Aspects of Male Libido Enhanced by Standardized *Trigonella foenum-graecum* Extract and Mineral Formulation. *Phytother Res* 2010; DOI: 10.1002/ptr.3360.
95. **Vitetta L, Beck S, Coulson S, Sali A.** Is it ethical for medical practitioners to prescribe alternative and complementary treatments? *MJA* 2011;195(8):450-451.
96. **Vitetta L, Sali A, Coulson S.** Soy and health: the latest evidence. *Medicine Today* 2011;12(3): 67-74.
97. Harris E, Kirk J, Rowsell R, **Vitetta L, Sali A, Scholey AB, Pipingas A.** The effect of multivitamin supplementation on mood and stress in healthy older males. *Human Psychopharmacology: Clinical and Experimental* 2011; 26:560-7.
98. Schoendorfer N, Tinggi U, Sharp N, Boyd R, **Vitetta L, Davies PSW.** Micronutrient intakes in orally and enterally fed children with severe Cerebral Palsy. *Clinical Nutrition eSPEN* 2011;6(6):e259-e263.
99. Schloss J, **Vitetta L.** Commentary: Cancer Chemotherapeutics, Chemotherapy Induced Peripheral Neuropathy (CIPN) and B Group Vitamins. *ACNEM Journal* 2012;31(2):24-28.
100. Schoendorfer N, Tinggi U, Sharp N, Kahlon P, Yates H, Boyd R, **Vitetta L, Davies PSW.** Protein levels in enteral feeds: Do these meet requirements in children with severe Cerebral Palsy *Br J Nutr* 2012;107:1476–1481.
101. Schoendorfer NC, Obeid R, Moxon-Lester L, Sharp N, **Vitetta L, Boyd RN, Davies PS.** Methylation capacity in children with severe cerebral palsy. *Eur J Clin Invest* 2012;42 (7):768–776.
102. Coulson S, Vecchio P, Gramotnev H, **Vitetta L.** Green-Lipped Mussel (*Perna canaliculus*) Extract Efficacy in Knee Osteoarthritis and Improvement in Gastrointestinal Dysfunction: A Pilot Study. *Inflammopharmacology* 2012;20(2):71-6.
103. **Vitetta L, Briskey D, Hayes E, Shing, C, Peake J.** Probiotics, Commensal Bacteria and the Pharmacobiotic Regulation of Gastrointestinal Inflammation. *Inflammapharmacology* 2012;20(5):251-266.

104. Harris E, McPherson H, **Vitetta L**, Kirk J, Sali A, Pipingas A. Effects of a multivitamin, mineral and herbal supplement on cognition and blood biomarkers in older males: A randomised, placebo-controlled trial *Human Psychopharmacology: Clinical and Experimental* 2012 DOI: 10.1002/hup.2236
105. **Vitetta L**, Couslon S, Schloss, J, Beck AL, Allen R, Sali A. Dietary recommendations for patients with rheumatoid arthritis: a review. *Nutr Dietary Supplem* 2012;4:1–15.
106. O'Brien K, **Vitetta L**. Potential role of botanicals for the treatment of chronic stable angina pectoris due to coronary heart disease. *Botanics: Targets and Therapy* 2012;3:1-17.
107. Coulson S, Butt H, Vecchio P, Gramotnev H, **Vitetta L**. Green-Lipped Mussel extract (*Perna canaliculus*) and Glucosamine sulphate in patients with knee Osteoarthritis: therapeutic efficacy and effects on gastrointestinal microbiota profiles. *Inflammopharmacology* 2013;21(1):79-90. DOI: 10.1007/s10787-012-0146-4.
108. Schoendorfer N, **Vitetta L**, Sharp N, Di Geronimo M, Wilson G, Coombes J, Boyd R, Davies PSW. Micronutrient, antioxidant and oxidative stress status in children with severe Cerebral Palsy. *JPEN J Parenter Enteral Nutr* 2013;37:97-101.
109. **Vitetta L**, Coulson S, Beck SL, Gramotnev H, Sharon Du S, Lewis S. Clinical Efficacy of a Bovine Lactoferrin / Whey Protein Ig-rich Fraction (Lf/IgF) for the Prevention of the Common Cold. *J Comp Ther in Medicine* 2013; 21(3):164-71.
110. Coulson S, Rao A, Beck SJ, Steels E, Gramotnev H, **Vitetta L**. A phase IIa randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. *J Comp Ther in Medicine* 2013; <http://dx.doi.org/10.1016/j.ctim.2013.01.007>.
111. **Vitetta L**, Gobe G. Uremia and Chronic Kidney Disease: The Role of Probiotics / Prebiotics. *Molecular Nutrition and Food Research* 2013; 57(5):824-32.
112. Marx WM, Teleni LX, McCarthy AL, **Vitetta L**, McKavanagh D, Thomson T, Isenring E. Ginger (*Zingiber officinale*) and chemotherapy-induced nausea and vomiting: a systematic literature review. *Nutrition Reviews* 2013; 71(4):245-54.
113. Schloss JM, Colosimo M, Airey C, **Vitetta L**. Nutraceuticals and Chemotherapy Induced Peripheral Neuropathy (CIPN): a Systematic Review. *Clinical Nutrition* 2013; doi:pii: S0261-5614(13)00107-6. 10.1016/j.clnu.2013.04.007.
114. Palacios T, Coulson S, Butt H, **Vitetta L**. The Gastrointestinal Microbiota and Multi-Strain Probiotic Therapy: In Children and Adolescent Obesity. *Advances Integrative Medicine* 2014;1:2-8.
115. Bella CJ, Coulson S, **Vitetta L**. Is co-prescribing a multi-strain probiotic the simple solution for treating and preventing Proton Pump Inhibitor (PPIs) induced *Clostridium difficile* Associated Diarrhoea (CDAD) while maintaining evidence based pharmacotherapy? Submitted *Advances Integrative Medicine* 2014;1:52-54.
116. Gray B, **Vitetta L**, Davies WP. Waist circumference and liver enzymes better predictors of adiponectin levels than BMI in overweight and obese adults. *Nutrition Research* 2013;33(10):781-788.
117. Shing CM, Peake J, Lim CL, Briskey D, Walsh NP, Fortes MB, Ahuja K, **Vitetta L**. Probiotic supplementation improves exercise performance in the heat. *European Journal of Applied Physiology*. 2013; 114(1):93-103.
118. Gray B, Steyn F, Davies PSW, **Vitetta L**. Omega-3 fatty acids: A review of the effects on adiponectin and leptin and potential implications for obesity management. *European Journal of Clinical Nutrition*. 2013 Oct 16. doi: 10.1038/ejcn.2013.197. [Epub ahead of print]
119. **Vitetta L**, Alford H. The Pharmacobiotic Potential of the Gastrointestinal Tract Micro-Biometabolome-Probiotic Connect: A Brief Commentary. *Drug Development Research* 2013;74:353-359.
120. **Vitetta L**, Linnane AW, Gobe GC. From the Gastrointestinal Tract (GIT) to the Kidneys: Live Bacterial Cultures (Probiotics) Mediating Reductions of Uremic Toxin Levels via Free Radical Signaling. *Toxins* 2013;5(11): 2042-2057.
121. **Vitetta L**, Couslon S, Linnane AW, Butt H. The Gastrointestinal Microbiome and Musculoskeletal Diseases: Is There a Role for Probiotics and Prebiotics? *Pathogens* 2013;2:606-626.
122. Couslon S, **Vitetta L**. A response to AIMA newsletter published 21<sup>st</sup> Jan 2014. Re: Multivitamins study.
123. **Vitetta L**, Linnane AW. Endocellular regulation by free radicals and hydrogen peroxide: key determinants of the inflammatory response. *Inflammopharmacology*. 2014; 22(2):69-72.
124. Scholoss, J, **Vitetta L**. Antioxidants to Abrogate Free Radicals: a billion dollar industry based on a chimeric notion without biological plausibility. New insights to challenge currently held beliefs. *Austral J of Herbal Med* 2014;26(1):4-6, 33.
125. **Vitetta L**, Briskey B, Alford H, Hall S, Coulson S. Probiotics and prebiotics and the gastrointestinal tract in health and disease. *Inflammopharmacology* 2014; 22(3):135-54.
126. **Vitetta L**, Hall S, Linnane AW. Live Probiotic Cultures and the Gastrointestinal Tract: Symbiotic Preservation of Tolerance Whilst Attenuating Pathogenicity. Invited Commentary. *Frontiers in Cellular and Infection Microbiology*. 2014; 4:143
127. **Vitetta L**, Linnane AW. Endocellular Regulation of Free Radicals and Hydrogen Peroxide: Key Determinants of the Inflammatory Response. *Inflammopharmacology* 2014;22(2):69-72.
128. Marx W, McCarthy A, Ried K, **Vitetta L**, McKavanagh D, Thomson D, Sali A, Isenring E. Can ginger ameliorate chemotherapy-induced nausea? A double blind, randomised placebo controlled trial. *Trials Journal* 2014;14(1):134.
129. Gray B, Steyn F, Davies WP, **Vitetta L**. Liver function parameters, cholesterol and phospholipid alpha linoleic acid predict adipokine levels in overweight and obese adults. *Nutrition Research* 2014; 34(5):375-82
130. **Vitetta L**, Manuel R, Zhou JY, Linnane AW, Hall S, Coulson S. The Overarching Influence of the Gut Microbiome on End-Organ Function: The Role of Live Probiotic Cultures. *Pharmaceuticals* 2014;7:954-989.
131. **Vitetta L**, Bambling M, Alford H. The Gastrointestinal Tract Microbiome, Probiotics and Mood. *Inflammopharmacology* 2014;22(6):333-9.
132. **Vitetta L**, Hall S, Linnane AW. Live Probiotic Cultures and the Gastrointestinal Tract: Symbiotic Preservation of Tolerance Whilst Attenuating Pathogenicity. *Frontiers in Cellular and Infection Microbiology* 2014 Oct 15;4:143

133. Liu X, **Vitetta L**, Kostner KM, Crompton D, Williams GM, Brown WJ, Lopez A, Xue C, Po Oei T, Byrne G, Martin J, Whiteford HA. The Effects of Tai Chi in Centrally Obese Adults with Depression Symptoms. Evidence-Based Complementary and Alternative Medicine Volume 2015, Article ID 879712, 8 pages <http://dx.doi.org/10.1155/2015/879712>
134. Marx W, Ried K, McCarthy A, **Vitetta L**, Sali A, McKavanagh D, Isenring E. Ginger - mechanism of action in chemotherapy-induced nausea and vomiting: a review. Critical Reviews in Food Science and Nutrition. 2015;April 7:0
135. Schloss JM, Colosimo M, Airey C, **Vitetta L**. Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Vitamin B12 Deficiency. Supportive Care in Cancer. 2015;23(7):1843-50.
136. Rao A, Steels E, Beccaria G, Inder WJ, **Vitetta L**. Influence of a Specialized Trigonellafoenum graecum Seed Extract (Libifem), on Testosterone, Estradiol and Sexual Function in Healthy Menstruating Women, a Randomised Placebo Controlled Study. Phytother Res 2015; 29(8):1123-30.
137. Bambling M, Edwards SC, Coulson S, **Vitetta L**. S-adenosylmethionine (SAME) and Magnesium Orotate as adjunctives to SSRIs in sub-optimal treatment response of depression in adults; a pilot study. Adv Integrative Medicine 2015;2:56-62.
138. **Vitetta L**. Lactobacillus acidophilus Restores Functionality in Uremic Macrophages: Plausible or Lacking Evidence? Dig Dis Sci 2016;61(6):1417-9.
139. Ellis RJ, Small DM, Vesey DA, Johnson DW, Francis R, **Vitetta L**, Gobe GC, Morais C. Indoxyl sulphate and kidney disease: causes, consequences and interventions. Nephrology (Carlton). 2016;21(3):170-177.
140. Morais C, **Vitetta L**. Journal of Controversies in Biomedical Research- the Need of the Hour. Journal of Controversies in Biomedical Research 2015; 1(1):1-3.
141. **Vitetta L**, Coulson S, Linnane AW. Reactive oxygen species in disease: rebuttal of a conventional concept. Journal of Controversies in Biomedical Research 2015;1(1):23-27.
142. Schloss J, Colosimo M, **Vitetta L**. New Insights into potential prevention and management options for chemotherapy-induced peripheral neuropathy: Asia-Pacific Journal of Oncology Nursing 2016; 3(1):73-85.
143. **Vitetta L**, Hall S, Coulson S. Metabolic Interactions in the Gastrointestinal Tract (GIT): Host, Commensal, Probiotics, and Bacteriophage Influences. Microorganisms 2015;3(4):913-932.
144. Chen C, Zhao KN, Masci PP, Lakhani SR, Antonsson A, Simpson PT, Vitetta L. TGFβ isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications. BMC Cancer. 2015 Dec 24;15(1):1010.
145. Rao A, Steels E, Inder WJ, Abraham S, Vitetta L. Testofen, a specialised Trigonella foenum-graecum seed extract reduces age-related symptoms of androgen decrease, increases testosterone levels and improves sexual function in healthy aging males in a double-blind randomised clinical study. Aging Male 2016;19(2):134-142.
146. Liu X, Furuya-Kanamori L, Siskind D, Crompton D, Williams GM, Kostner K, **Vitetta L**, Doi SA. An evidence-based scale for the antecedents of depressive symptoms in Australian adults. Australas Psychiatry. 2016;24(5):466-469.
147. Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN, Crawford D, Campbell C, **Vitetta L**. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Therap Adv Gastroent 2016;9(4):463-72.
148. Schloss J, Colosimo M, Airey C, Masci P, Linnane A, **Vitetta L**. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Supportive Care in Cancer 2016;25(1):195-204.
149. **Vitetta L**, Saltzman ET, Nikov T, Ibrahim I, Hall S. Modulating the Gut Micro-Environment in the Treatment of Intestinal Parasites. J Clin Med 2016;5(11) pii: E102.
150. Schloss J, Colosimo M, **Vitetta L**. Herbal Medicines and Chemotherapy Induced Peripheral Neuropathy (CIPN): a Critical Review. Critical Reviews in Food Science and Nutrition 2017;57(6):1107-1118.
151. Palacios T, **Vitetta L**, Coulson S, Madigan CD, Denyer GS, Caterson ID. The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized double-blind placebo-controlled pilot study. Trials. 2017;18(1):7
152. **Vitetta L**, Coulson S, Thomsen M, Nguyen T, Hall S. Gut Microbes Manuscript Type: Commentary and Views Submission. Probiotics, D-Lactic Acidosis, Oxidative Stress and Strain Specificity. Gut microbes. 2017;12:1-12.
153. Bambling M, Edwards SC, Hall S, **Vitetta L**. A combination of probiotics and magnesium orotate attenuate depression in a small SSRI resistant cohort: an intestinal anti-inflammatory response is suggested. Inflammopharmacology. 2017; 25(2):271-274.
154. Heritage ML, Jaskowski LA, Bridle KR, Campbell C, Briskey D, Britton LJ, Fletcher LM, **Vitetta L**, Nathan Subramaniam V, Crawford DHG. Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in *Hfe<sup>-/-</sup>* mice. World Journal of Gastrointestinal Pathophysiology 2017; 8(2):67-76.
155. Saltzman, ET, Thomsen M, Hall S, **Vitetta L**. Perna canaliculus and the Intestinal Microbiome. Mar Drugs 2017;15(7):pii:E207.
156. Marx W, McCarthy AL, Ried K, McKavanagh D, **Vitetta L**, Sali A, Lohning A, Isenring E. The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial. Nutrients 2017;9(8). pii: E867.
157. Detering M, Steels E, Koyyalamudi SR, Alliffranchini E, Bocchietto E, **Vitetta L**. Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study. Biofactors 2017;43(6):789-800.
158. **Vitetta L**, Saltzman ET, Thomsen M, Nikov T, Hall S. Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes. Vaccines 2017;5:50.

159. **Vitetta L**, Saltzman ET, Thomsen M, Nikov T, Hall S. Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes. *Vaccines (Basel)*. 2017;5(4). pii: E50.
160. **Vitetta L**. Probiotics Can Break the Toxic Relationship Between the Intestinal Microbiome and the Kidney. *Dig Dis Sci* 2018; 64(2):297-299.
161. **Vitetta L**, Zhou J, Manuel R, Dal Forno S, Hall S, Rutolo D Route and Type of Formulation Administered Influences the Absorption and Disposition of Vitamin B<sub>12</sub> Levels in Serum. *J Funct Biomater*, 2018;9(1):pii: E12.
162. Saltzman ET, Palacios T, Thomsen M, **Vitetta L**. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. *Front Microbiol* 2018;9:61. eCollection.
163. **Vitetta L**, Vitetta G, Hall S. The Brain-Intestinal Mucosa-Appendix- Microbiome-Brain Loop. *Diseases*. 2018;6(2). pii: E23
164. Ellis RJ, Small DM, Ng KL, Vesey DA, **Vitetta L**, Francis RS, Gobe GC, Morais C. Indoxyl sulfate induces apoptosis and hypertrophy in human kidney proximal tubular cells. *Toxicologic Pathology* 2018;46(4):449-459.
165. Correction: **Vitetta L**, et al., Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes. *Vaccines* 2018;6(2):pii:E26.
166. Chen J, **Vitetta L**. Inflammation-Modulating Effect of Butyrate in the Prevention of Colon Cancer by Dietary Fiber Clin Colorectal Cancer. 2018;7(3):e541-e544.
167. Thomsen M, Clarke S, **Vitetta L**. The Role of Adjuvant Probiotics to Attenuate Intestinal Inflammatory Responses due to Cancer Treatments. *Beneficial Microbes*, 2018;20:1-18.
168. Chen J, **Vitetta L**. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of NAFLD and potential therapeutic implications of probiotics. *Journal of Cellular Biochemistry*, 2018;120(3):2713-2720.
169. **Vitetta L**, Vitetta G, Hall S. Immunological Tolerance and Function: Bacteria, Probiotics, Prebiotics and Phages. *Frontiers in Immunology*, 2018;9:2240.
170. Chen J, **Vitetta L**. Comments on "Supplementation with *Lactobacillus reuteri* ATCC PTA 4659 in patients affected by acute uncomplicated diverticulitis: a randomized double-blind placebo-controlled trial. *Internat J Colorect Dis* 2019; 34(98):1503-1504.
171. Chen J, **Vitetta L**. Activation of T-regulatory cells by a synbiotic may be important for its anti-inflammatory effect. *Eur J Nutr* 2019;58(8):3379-3380.
172. Chen J, **Vitetta L**. Bile acids and butyrate in the effects of probiotics/synbiotics on NAFLD. *Eur J Gastroenterol and Hepatol* 2019;31(11):1475-1476.
173. Chen J, Thomsen M, **Vitetta L**. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. *J Cell Biochem*, 2019;120(3):2713-2720.
174. **Vitetta L**, Leong A, Zhou J, Dal Forno S, Hall S, Rutolo D. The Plasma Bioavailability of Coenzyme Q<sub>10</sub> Absorbed from the Gut and the Oral Mucosa. *J Funct Biomater* 2018;9(4):pii: E73.
175. **Vitetta L**, Chen J, Clarke S. The vermiform appendix: an immunological organ sustaining a microbiome inoculum. *Clinical Science*, 2019;133(1):1-8.
176. Steels E, Venkatesh R, Steels E, Vitetta G, **Vitetta L**. A double-blind randomized placebo-controlled study assessing safety, tolerability and efficacy of Palmitoylethanolamide for symptoms of knee osteoarthritis. *Inflammopharmacol* 2019;27(3):475-485.
177. Chen J, Zhao KN, **Vitetta L**. Effects of Intestinal Microbial-Elaborated Butyrate on Oncogenic Signaling Pathways. *Nutrients* 2019;11(5):pii: E1026.
178. Thomsen M, **Vitetta L**. Zinc deficiency and mucositis – is there a relationship? *Curr Opin Clin Nutr Metab Care* 2019; Jul 16.
179. **Vitetta L**, Llewellyn H, Oldfield D. Gut Dysbiosis and the Intestinal Microbiome: Is *Streptococcus thermophilus* Key to Reducing Uremia? *Microorganisms* 2019; Jul 31;7(8):pii: E228.
180. Chen J, **Vitetta L**. Mitochondria could be a key mediator in the effect of intestinal microbiota on depression. *Journal of Cellular Biochemistry* 2020;121(1):17-24.
181. Chen J, **Vitetta L**. Signalling molecules and epigenetic targeting in cancer immunotherapy - Comments on "Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma". *Cellular Immunology*. 2019;346:103957.
182. **Vitetta L**, Henson JD. Probiotics and Synbiotics Targeting the Intestinal Microbiome Attenuate Nonalcoholic Fatty Liver Disease (NAFLD). *Hepatobiliary Surgery and Nutrition* 2020; 9(4):526-529.
183. **Vitetta L**. Mind Body Medicine: A Tangible Link Between the Gut and the Brain. *Annals of Translational Medicine* 2020;8(4):64.
184. Chen J, **Vitetta L**. The Role of Butyrate in Attenuating Pathobiont-Induced Hyperinflammation. *Immune Network* 2020;20(2):e15.
185. **Vitetta L**, Butcher B, Del Forno S, Vitetta G, Nikov T, Hall S, Steels E. A double-blind randomized placebo-controlled study assessing the safety, tolerability and efficacy of a herbal medicine containing pycnogenol combined with papain and aloe vera in the prevention and management of pre-diabetes. *Medicines* 2020;7(4):22
186. Chen J, **Vitetta L**. Should butyrate be incorporated into FXR agonist for PSC treatment? Commentary on: FXR agonist Cilofexor improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. *Hepatology* 2020.
187. Chen J, **Vitetta L**. Gut microbiota and therapeutic intervention for NAFLD. Invited Review. *Intern J Mol Sci* 2020.
188. Chen J, Sali A, **Vitetta L**. The gallbladder and vermiform appendix influence the assemblage of intestinal microorganisms. *Future Microbiol* 2020;15:541-555.
189. Palacios T, **Vitetta L**, Coulson S, Madigan CD, Lam YY, Manuel R, Briskey D, Hendy C, Ishoey T, Soto J, Kim J, Schott E, Toledo G and Caterson ID. The effect of a multi-strain probiotic on metabolic and inflammatory markers in adults with

- prediabetes and recently diagnosed type 2 diabetes mellitus: a randomised controlled pilot study. *Nutrients* 2020;12(7):E2041.
190. Chen J, **Vitetta L**. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. *Intern Journal Mol Sci* 2020;21(15):5214.
  191. Osborne SA, Du QS, Masci PP, Daniel RA, Desilva K, **Vitetta L**, Zhao KN, Seymour RB. Oral administration of dermatan sulfate from bovine collagen waste liquor reduces venous thrombus formation *in vivo*. *Inflammopharmacology* 2020;29(2):525-535.
  192. Chen J, Hall S, **Vitetta L**. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. *Med Rev Virol* 2021;31(5):1-13.
  193. Chen J, **Vitetta L**. Increased PD-L1 expression may be associated with the cytokine storm and CD8+ T-cell exhaustion in severe Covid-19. *Journal of Infectious Diseases* 2021;223(9):1659-1660.
  194. Chen J, **Vitetta L**. Gut-brain axis in the neurological complications of COVID-19. *Brain Commun* 2021; May 27;3(2):fcab118.
  195. Daniels K, **Vitetta L**, Fiatarone Singh M. Effects of olives and their constituents on the expression of ulcerative colitis: a systematic review of murine model trials. *Br J Nutrition* 2021; Jun 8: 1-19.
  196. **Vitetta L**, Sikali JF. Comment on: Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in patients with chronic pain. *Can J Anaesth* 2021;68(11):1707-1708.
  197. **Vitetta L**, Butcher B, Henson JD, Rutolo D, Hall S. A Pilot Safety, Tolerability and Pharmacokinetic Study of Oro-buccal Administered Cannabidiol Dominant Formulation in Healthy Individuals: A Randomized Placebo Controlled Single-Blinded Study. *Inflammopharmacol* 2021;29(5):1361-1370.
  198. Chen J, **Vitetta L**. The gut-liver axis in chronic liver disease - associated with severe COVID-19. *Eur J Gastroenterol Hepatol* 2021; 33(1S Suppl 1):e1103.
  199. Chen J, **Vitetta L**. Comment on: Microbiome signatures of progression toward celiac disease onset in at-risk children in a longitudinal prospective cohort study. *PNAS USA* 2021; Oct 12;118(41):e2113655118.
  200. Chen J, **Vitetta L**, Henson JD, Hall S. The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. *J Funct Foods* 2021 Dec; 87:104850.
  201. Henson JD, **Vitetta L**, Quezada M, Hall S. Enhancing Endocannabinoid Control of Stress with Cannabidiol. *J Clin Med* 2021;10(24):5852.
  202. Chen J, **Vitetta L**. The gut-liver axis in chronic liver disease - associated with severe COVID-19. *Eur J Gastroenterol and Hepatol* 2021;33(1S Suppl 1):e1103.
  203. Chen J, **Vitetta L**. Gut Dysbiosis Could Be a Major Factor for the Effects of Low-Grade Endotoxemia in COVID-19. Comment on: Low-Grade Endotoxemia and Thrombosis in COVID-19. *Clin Transl Gastroenterol* 2022;13(1):e00440.
  204. Chen J, **Vitetta L**, Henson JD, Hall S. Intestinal dysbiosis, the tryptophan pathway and Nonalcoholic Steatohepatitis (NASH). *International Journal of Tryptophan Research*. 2022; Feb 7;15:11786469211070533.
  205. **Vitetta L**, Sikali JF, Fletcher C, Henson JD. Comment on: Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences. *Support Care in Cancer* 2022 Mar 21. doi: 10.1007/s00520-022-06995-7.
  206. **Vitetta L**, Andersen T, Quezada M, Rutolo D, Henson JD. Re: "Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial" by Crippa et al. *Cannabis Cannabinoid Res* 2022;7(2):231-233.
  207. Chen J, **Vitetta L**. The role of the gut-lung axis in COVID-19 infections and its modulation to improve clinical outcomes. *Frontiers in Bioscience-Scholar* 2022. **In Press**
  208. **Vitetta L**. Can krill oil from small crustaceans be a panacea that alleviates symptoms of knee osteoarthritis? *Amer J Clin Nutr* 2022; **In Press**
  209. Ritchie G, Strodl E, Parham S, Bambling M, **Vitetta L**. The gut microbiota in major depression with anxious distress. *J Affect Dis* 2022 **In Press**  
Henson JD, Vitetta L, Hall S. Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. *Inflammopharmacology* 2022 **In Press**
  210. Clarke S, Butcher BB, McLachlan AJ, Henson JD, Rutolo D, Hall S, **Vitetta L**. Pilot Clinical and Pharmacokinetic Study of  $\Delta^9$ -Tetrahydrocannabinol (THC) / Cannabidiol (CBD) Nanoparticle Oro-Buccal Spray in Patients with Advanced Cancer Experiencing Uncontrolled Pain. *PLOS ONE* 2022 **In Press**

---

### Currently Under Review

- Pickering E, Steels EL, Steadman KJ, Rao A, PhD, **Vitetta L**. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. **Amer J Clin Nutr**

### Abstracts / Proceedings

1. Nayman J, **Vitetta L**, Hocking C, Sali A. Primary bile duct stones. *Royal Australasian College of Surgeons Aust NZ J Surg* 52:280-281 1981. Sydney Australia.

2. Sali A, **Vitetta L**, Hocking C, Kune GA, Nayman J. The Composition of primary bile duct stones. 7<sup>th</sup> World CICD Congress on Gastroenterology. Digs Surg J 1:F018, 1982. Tokyo Japan.
3. Sali A, **Vitetta L**, Hocking C, Kune GA. In vitro dissolution of cholesterol gallstones with citrate. 7<sup>th</sup> World CICD Congress on Gastroenterology. Digs Surg J 1:R52, 1982. Tokyo Japan.
4. **Vitetta L**, Sali A, Hocking C, Thomson G. Calcified cholesterol gallstones and citrate. 1<sup>st</sup> Australian Postgraduate Research Meeting. APRC Proc 1, 1983. Sydney Australia.
5. **Vitetta L**, Sali A, Hocking C, Thomson G. Primary bile duct stone composition suggests an etiology different to that of gallbladder stones. 1<sup>st</sup> Australian Postgraduate Research Meeting. APRC Proc 1, 1983. Sydney Australia.
6. Sali A, **Vitetta L**, Hocking C, Thomson G, Kune GA. Dissolution of calcified cholesterol gallstones with citrate. 30<sup>th</sup> World CISS Conference in Surgery. World J Surg 90, 1983. Hamburg Germany.
7. **Vitetta L**, Sali A, Chou ST, Fleming H. Gallstone incidence and composition. Royal Australasian College of Surgeons. Aust NZ J Surg 14, 1984. Melbourne Australia.
8. Sali A, **Vitetta L**, Chou ST, Fleming H. Gallstone incidence and composition in Australia. 8<sup>th</sup> World CICD Congress on Gastroenterology. Digs Surg J W047, 1984. Amsterdam.
9. **Vitetta L**, Coloe S, Carsons P, Thomson G, Sali A. The role of bacteria in the etiology of gallstones. Royal Australasian College of Surgeons. Aust NZ J Surg 137, 1985. Sydney Australia.
10. **Vitetta L**, Sali A, Moritz V, Shaw A. Gallstones and bacteria. 9<sup>th</sup> World CICD Congress on Gastroenterology. In: Dig Surg J 1986;3(2) :106. Jerusalem Israel 1985. [Dig Surg 1986;3(2):63–198 (DOI:10.1159/000171727)].
11. **Vitetta L**, Sali A, Moritz V, Shaw A. Is the etiology of primary choledocholithiasis unique? 9<sup>th</sup> World CICD Congress on Gastroenterology. In: Dig Surg J 1986;2(3):126. Jerusalem, Israel 1985. [Dig Surg 1986;3(2):63–198 (DOI:10.1159/000171727)]
12. **Vitetta L**, Sali A, Little P. Do primary bile duct stones occur in the duct? Royal Australasian College of Surgeons. Aust NZ J Surg 209, 1986 Adelaide Australia 1986.
13. **Vitetta L**, Sali A, Elzarka A. Primary bile duct stone etiology: a role for bacterial  $\beta$  glucuronidase. 32<sup>nd</sup> World CISS Conference in Surgery. World J Surg 43, 1987. Sydney Australia.
14. Kune GA, Kune S, Watson LF, Pierce RJ, **Vitetta L**, et al. Serum levels of vitamin A,  $\beta$  carotene and zinc in male lung cancer cases and controls. 14<sup>th</sup> Annual Meeting Clinical Oncological Society of Australia. Clin Oncol Soc Aust 98, 1987 Perth Australia.
15. Pierce RJ, Watson LJ, Kune GA, Kune S, **Vitetta L**, et al. Smoking pattern occupational risk family history dietary and alcohol intake in lung cancer. Thoracic Society of Australia and New Zealand. 46, 1987 Perth Australia.
16. RJ Pierce, LF Watson, GA Kune, S Kune, L Vitetta, B Filed, D Merenstein, A Hey, LB Irving. Smoking pattern occupational risk family history dietary and alcohol intake in lung cancer: results of a case control study. Proceedings of the British Thoracic Society, Scottish Thoracic Society and Thoracic Society of Australia. 707. In: Thorax 1987;42:705-752. University of Edinburgh, Edinburgh, Scotland. 1987.
17. Sali A, **Vitetta L**. Dissolution and decalcification of gallstones with chenodeoxycholate and citrate. Royal Australasian College of Surgeons Aust NZ J Surg 250, 1988. Brisbane Australia.
18. Gya D, Sali A, **Vitetta L**, Eu P. Limy bile cholecystitis: a case report and an in vitro study. Royal Australasian College of Surgeons Aust NZ J Surg 389, 1989. Melbourne Australia.
19. **Vitetta L**, A Sali. Is infection a cause of cholesterol gallstones. Royal Australasian College of Surgeons Aust NZ J Surg 328, 1989. Melbourne Australia.
20. Fukuma E, **Vitetta L**, A Sali. Composition of intrahepatic stones. Proceedings World Gastroenterology Conference Gastroenterol 215,1990. Sydney Australia.
21. **Vitetta L**, Moritz V, Mayall B, Sali A. Cholesterol gallstones and bacteria Royal Australasian College of Surgeons Aust NZ J Surg 1996;545, Melbourne Australia.
22. **Vitetta L**, Sali A. Gallstones and gallbladder carcinoma Royal Australasian College of Surgeons Aust NZ J Surg 1996;666, Melbourne Australia.
23. **Vitetta L**, Sali A, Moritz V, Mayall B. Bacteria and cholesterol gallstones 15<sup>th</sup> World CICD Conference Digs Surg 90, 1996 Seoul South Korea.
24. Gersh W, **Vitetta L**, McEvoy A, Mrazek L, Sali A. A National Needs Assessment of Parents of Children with Inflammatory Bowel Disease 7<sup>th</sup> Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology and Nutrition Proceedings in Paediatrics Cairns Australia 2001.
25. **Vitetta L**, Sali A, Paspaliaris B, Lilttle P, Jones T. Cholesterol Solitaire Gallstones and Bacterial Infections. 4<sup>th</sup> Congress of the European chapter of the international HPB Association Proceedings HBP 3(1):26 Amsterdam 2001.
26. **Vitetta L**, Sali A, Little P, Jones T. Brown Pigment Gallstones and Cholesterol Precipitates 4<sup>th</sup> Congress of the European chapter of the international HPB Association Proceedings HBP 3(1):26 Amsterdam 2001.
27. **Vitetta L**, Sali A, Jones T, Little P. Brown pigment gallstone formation: bacteria and precipitates of mucous, pigment and cholesterol. 18<sup>th</sup> World Congress and 9<sup>th</sup> Hong Kong International Cancer Congress. Hong Kong 2002.
28. **Vitetta L**, Cortizo F, J, Walker R, Rollo D, Sali A. Primary Care Cardiovascular Prevention: A System Using Absolute Risk, Pulse Wave Velocity, Heart Rate Variability, Blood Pressure and an Electrocardiogram. 25<sup>th</sup> Scientific Meeting of the Inter-American Society of Hypertension. 27-30 April 2003 San Antonio, US.
29. Reavley N, **Vitetta L**, Cortizo F, Sali A. A preliminary report of the effect of psychosocial support on the psychological and physical wellbeing of a heterogeneous group of cancer patients. Psycho Oncology 2004; 13: S51.

30. Thomsen M, Flannery G, **Vitetta L**, Schmidt M, Sali A. Herbal Preparation - Ginseng / Dang Gui Ten Combination (PS10) and Immune Response in Humans. International Congress on Natural Products Research (ICNPR) Proceedings 2004. Phoenix US.
31. Reavley N, **Vitetta L**, Cortizo F, Sali A. A preliminary report of the effect of psychosocial support on the psychological and physical wellbeing of a heterogeneous group of cancer patients – a further update. Australian Resource Centre for Healthcare Innovations Conference. 2004. Gold Coast Australia.
32. Di Vincenzo R, **Vitetta L**, Ng F, Cortizo F, Sali A. Nutritional and lifestyle factors influencing the development and progression of NIDDM in lean adult Vietnamese. Australian Resource Centre for Healthcare Innovations Conference. Gold Coast Australia 14-15<sup>th</sup> October 2004.
33. Harris E, Pipingas A, Kirk J, **Vitetta L**. The effect of multivitamin supplementation on cognition in adults at risk of cognitive decline. 15th Australasian Society for Psychophysiology Conference–Wollongong, Australia. In Journal of EEG and Clinical Neuroscience. Wollongong, Australia, 9-11<sup>th</sup> December 2005.
34. Pipingas A, Silberstein R, **Vitetta L**, Van Rooy C, Nastase J, Sali A. The Effects of an Extract of *Pinus Radiata* Pine Bark (Enzogenol) on Cognitive Function in Individuals at Risk of Cognitive Decline. 15th Australasian Society for Psychophysiology– Wollongong, Australia. In Journal of EEG and Clinical Neuroscience. Wollongong, Australia 9-11<sup>th</sup> December 2005.
35. Wang Y, Cicuttini FM, **Vitetta L**, Wluka AE What effect do dietary antioxidants have on the symptoms and structural progression of knee osteoarthritis over 2 years? Annual Scientific Meeting of the Australian Rheumatology Association, Melbourne 2005. Internal Medicine Journal 2005 (Suppl.);35:A89–A116.
36. Harris E, Pipingas A, Kirk J, **Vitetta L**, Downey LA. The Effects of Multivitamin Supplementation on Cognition in Adults at Risk of Cognitive Decline. 7<sup>th</sup> International Conference and Exhibition on Nutraceuticals and Functional Foods. Reno US, November, 2006.
37. **Vitetta L**, Sali A, Reavley N. Positive Thinking, Diet, Meditation and Psychosocial Support and Its Effects On The Psychological And Physical Wellbeing Of Cancer Patients. 3<sup>rd</sup> International Congress on Complementary Medicine Research, 29-31 Mar 2008. Sydney, Australia. S90.
38. **Vitetta L**, Poon HY, Sali A. HIV/AIDS and Complementary and Alternative Medicine (CAM) A Clinical Trial With A Traditional Chinese Medicine (TCM) / Yeast Preparation. 3<sup>rd</sup> International Congress on Complementary Medicine Research. 29-31 Mar 2008. Sydney, Australia.
39. Harris E, Kirk J, Vitetta L, Sali A, Pipingas A. Improvement of depressive symptoms in the elderly following multivitamin supplementation. 3<sup>rd</sup> International Congress on Complementary Medicine Research. 29-31 Mar 2008. Sydney, Australia S35.
40. **Vitetta L**, Harris E, Kirk J, Pipingas, A Sali A. Cognitive Decline in at Risk Adults and the Effect of a Multivitamin/Mineral Supplement. Heart Foundation Conference 14-16 May 2009 Brisbane, Australia. P109.
41. Coulson S, **Vitetta L**. Green-Lipped Mussle Extract and GIT Function in Patients Diagnosed with OA of the Knee. In:15<sup>th</sup> International Holistic Health Conference. Melbourne, Australia, 9-11 October 2009.
42. **Vitetta L**. Mitochondrial Metabolism, Nutraceuticals and Cognitive Decline with Ageing. In: 15<sup>th</sup> International Holistic Health Conference. Melbourne, Australia, 9-11 October 2009.
43. Schoendorfer N, **Vitetta L**, Boyd R, Davies PSW. Is the methyl folate trap responsible for growth stunting found in children with severe cerebral palsy? 50<sup>th</sup> Annual Meeting of the European Society for Paediatric Research Acta Paediatrica 2009;98 Suppl 460: 230. Hamburg, Germany, 9-12 Oct 2009.
44. Schoendorfer N, Tinggi U, Boyd R, **Vitetta L**, Davies PSW. Micronutrient intakes in children with cerebral palsy. [19<sup>th</sup> International Congress of Nutrition] Annals of Nutrition and Metabolism 2009;55 Suppl 1: 481.
45. Schoendorfer N, Boyd R, **Vitetta L**, Tinggi U, Coombes J, Davies PSW. Micronutrient status in children with cerebral palsy and the impact of a major orthopaedic surgical intervention. [19<sup>th</sup> International Congress of Nutrition] Annals of Nutrition and Metabolism 2009;55 Suppl 1: 484.
46. Schoendorfer N, Boyd R, **Vitetta L**, Tinggi U, Coombes J, Davies PSW. Micronutrient status in children with cerebral palsy [Nutrition Society of Australia and Nutrition Society of New Zealand. Thirty-third Annual Scientific Meeting]. 8-11 Dec, 2009 Newcastle, Australia. Australasian Medical Journal 2010; 3(1):55.
47. Schoendorfer N, Boyd R, **Vitetta L**, Tinggi U, Coombes J, Davies PSW. Micronutrient status in children with cerebral palsy. 5<sup>th</sup> Biennial Conference of the Australasian Academy of Cerebral Palsy & Developmental Medicine [Developmental Medicine and Child Neurology-Special Issue] Christchurch, NZ 3-6 Mar 2010; 52 Suppl 2:47.
48. Coulson S, Beck S, Gramotnev H, Masci P, **Vitetta L**. A Randomised Double Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of a Lactoferrin / Whey Protein Ig-Rich Fraction to Prevent the Onset of a Cold or Reduce Time of Symptoms in Patients with a Cold. In: 16<sup>th</sup> International Holistic Health Conference, Sunshine Coast, Australia, 3-5 September, 2010.
49. Schloss J, Colosimo M, Linnane AW, Masci P, **Vitetta L**. A Pilot Clinical Trial Assessing the efficacy and Safety of supplementation with vitamin B12 and other B vitamins to reduce the incidence of chemotherapy induced peripheral neuropathy [CIPN] in patients diagnosed with a malignancy. In: 16<sup>th</sup> International Holistic Health Conference, Sunshine Coast, Australia, 3-5 September, 2010.
50. Chen CF, Zhao KN, Linnane AW, Masci P, **Vitetta L**. The *in vitro* and *in vivo* effects of pharmacologic doses of ascorbate on cancer. In: 16<sup>th</sup> International Holistic Health Conference, Sunshine Coast, Australia, 3-5 September, 2010.
51. Gray B, **Vitetta L**, Coulquon D, Masci P. Marine Lipid Supplementation. Obesity: The Effect On Adiponectin And Leptin. In: 19<sup>th</sup> annual RBWH Health Care Symposium. Brisbane 2010.

52. Schoendorfer N, Tinggi U, Sharp N, **Vitetta L**, Davies PSW. Does enteral feeding compare with orally fed children with cerebral palsy or typically developing children? Nutrition Society of Australia thirty-fourth Annual Scientific Meeting [Australasian Medical Journal] 30 Nov-3 Dec 2010;3(13):880.
53. **Vitetta L**. The role of intravenous [IV] Vitamin C [Ascorbate] in the therapeutic treatment of Cancer. 1<sup>st</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. May13-15;2011;71-72. Sydney, Australia.
54. **Vitetta L**. Probiotics: An Update. 1<sup>st</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. May13-15;2011;72. Sydney, Australia.
55. Chen C, Zhao KN, Masci P, Linnane AW, **Vitetta L**. Mathematical Modelling and Molecular Mechanism of Pharmacologic Ascorbate-Induced Cytotoxicity in Cancer Cells. 1<sup>st</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. May 13-15;2011;78. Sydney, Australia.
56. Coulson S, Vecchio P, Masci P, **Vitetta L**. A Randomized Phase-I/Pilot Comparison Trial Evaluating the Efficacy of Nutraceutical Compounds In Patients With Osteoarthritis Of The Knee – Therapeutic Outcome Measures Correlated To Gastrointestinal Integrity. 1<sup>st</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2011;80. May13-15. Sydney Australia.
57. Gray B, **Vitetta L**, Colquhoun D, Masci P. Omega-3 Fatty Acid Supplementation In Obesity: The Effect On Adiponectin, Leptin And Insulin Sensitivity. 1<sup>st</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. May 13-15;2011;86. Sydney Australia.
58. Schloss J, Colosimo M, Linnane AW, Masci P, **Vitetta L**. A Randomised Placebo Controlled Clinical Trial Assessing The Efficacy And Safety Of Supplementation With B Vitamins To Reduce The Incidence Of Chemotherapy Induced Peripheral Neuropathy [CIPN]. 1<sup>st</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. May 13-15;2011;104. Sydney, Australia.
59. Schoendorfer N, Schafer J, **Vitetta L**, Davies, PW. Nutrition Integration into MBBS Programme: A Pilot Project. 1<sup>st</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. May 13-15;2011;105. Sydney, Australia.
60. Shing CM, Peake JM, Lim F, Briskey D, **Vitetta L**. Response to exercise in the heat following a period of probiotics supplementation. 16<sup>th</sup> Congress of the European College of Sports Science in Liverpool July 6-9, 2011.
61. Shing CM, Peake JM, Lim F, Briskey D, **Vitetta L**. Response to exercise in the heat following a period of probiotics supplementation. 10<sup>th</sup> Symposium of International Society of Exercise and Immunology in Oxford in July 11-13, 2011.
62. Sali A, Pipingas A, Harris E, Kirk J, **Vitetta L**. Use of a Multivitamin, Mineral and Herbal Supplement to improve Memory, Mood and Stress. 4<sup>th</sup> European Congress for Integrative Medicine. Berlin, Germany, Oct 7-8 2011.
63. Coulson S, Vecchio P, Butt H, Masci P, **Vitetta L**. Investigating Gastrointestinal Function And Microbiota Profiles In Patients With Osteoarthritis – A Role For Glucosamine And Green-Lipped Mussel. World Congress on Debates and Consensus in Bone, Muscle and Joint Diseases. Barcelona, Spain January 19-22, 2012.
64. **Vitetta L**. Probiotics and the Gastrointestinal Tract Microbiome in Musculoskeletal Disease. 2<sup>nd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
65. **Vitetta L**, Coulson S, Beck SL, Gramotnev H, Du S, Lewis S. Bovine Lactoferrin / Whey Protein Ig-rich Fraction (Lf/IgF) Combination for the Common Cold: A Randomized Placebo Controlled Clinical Trial. 2<sup>nd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
66. Briskey D, Heritage ML, Jaskowski LA, Fletcher LM, Subramaniam VN, Anderson GJ, Crawford DHG, Peake J, **Vitetta L**. A Multi-Strain Probiotic Retards Non-Alcoholic Fatty Liver Disease Progression In Mice Fed A High Fat Diet. 2<sup>nd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
67. Coulson S, Vecchio P, Butt H, Masci P, **Vitetta L**. Metabolic Potential Of Gastrointestinal Microbiota Profiles In Patients With Osteoarthritis – Implications For The Therapeutic Activity Of Glucosamine And Green-Lipped Mussel. 2<sup>nd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
68. Chen C, Zhao KN, Masci P, Linnane AW, **Vitetta L**. Molecular Mechanisms of Pharmacologic Ascorbate-induced Cytotoxicity in Cancer Cells. 2<sup>nd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
69. Gray B, Colquhoun D, Steyn D, Russell A, Muhlhausler B, **Vitetta L**. Reducing Fatigue in Obesity: An Observational Study Investigating The Potential Role Of Omega-3 Essential Fatty Acids. 2<sup>nd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
70. Schoendorfer N, Obeid R, Sharp N, **Vitetta L**, Boyd R, Davies P. Altered DNA methylation and one-carbon metabolism: A case for the methyl-folate trap? 2<sup>nd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2012; May 4-6. Melbourne Australia.
71. Martensen R, Coulson S, Isenring E, **Vitetta L**. Reducing the risk of developing *Clostridium difficile* infections/diarrhoea by co-prescribing a multi-strain probiotic with proton pump inhibitor [PPIs] medications. In: 18<sup>th</sup> International Integrative Medicine Conference, Melbourne, Australia, 31 Aug-2 Sep, 2012.
72. Coulson S, Butt H, Vecchio P, Gramotnev H, **Vitetta L**. Gastrointestinal Microbiota Profiles in Patients with Osteoarthritis – Implications for the Therapeutic Activity of Green-Lipped Mussel (*Perna canaliculus*) and Glucosamine. In: 18<sup>th</sup> International Integrative Medicine Conference, Melbourne, Australia, 31 Aug-2 Sep, 2012.
73. **Vitetta L**. Gastrointestinal Dysbiosis and Probiotics in Musculoskeletal Medicine In: 18<sup>th</sup> International Integrative Medicine Conference, Melbourne, Australia, 31 Aug-2 Sep, 2012.
74. Palacios T, Coulson S, Butt H, Leong G, Dahiya R, **Vitetta L**. Gut Microbiota and Metabolic Syndrome: How a Multi-Strain Probiotic may Influence Biomarkers in Obese Adolescents. 3<sup>rd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.

75. Coulson S, Palacios T, Butt H, Leong G, Dahiya R, **Vitetta L**. The Role of Gut Microbiota in Non-Alcoholic Fatty Liver Disease: The Efficacy of a Multi-Strain Probiotic in Obese Adolescents. 3<sup>rd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.
76. Steels E, Rao A, Coulson S, **Vitetta L**. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. 3<sup>rd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.
77. Schloss J, Colosmio M, Linnane AW, Masci P, **Vitetta L**. B Vitamin Status In Cancer Patients Administered Chemotherapy. 3<sup>rd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.
78. Marx W, Ried K, Sali A, Teleni L, McCarthy A, **Vitetta L**, McKavanagh D, Thomson D, Isenring E. Is Ginger Supplementation Effective In Ameliorating Chemotherapy-Induced Nausea And Vomiting? 3<sup>rd</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2013; May 3-5. Sydney Australia.
79. Schloss J, Colosmio M, Linnane AW, Masci P, Vitetta L. A Randomised Placebo-Controlled Clinical Trial Assessing The Efficacy And Safety Of Supplementation With B Vitamins To Reduce The Incidence Of Chemotherapy-Induced Peripheral Neuropathy [CIPN], Final Results. 4<sup>th</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2014; May 3-5. Gold Coast, Australia.
80. Palacios T, Coulson S, Butt H, Vitetta L. The Effect Of Microbiota-Based Interventions And Metformin In Metabolic And Inflammatory Biomarkers In Adults With Type 2 Diabetes Mellitus (T2DM). 4<sup>th</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2014; May 3-5. Gold Coast, Australia.
81. Marx W, McCarthy AL, Ried K, **Vitetta L**, McKavanagh D, Thomson D, Sali A, Isenring L. Ginger-Mechanism Of Action In Chemotherapy-Induced Nausea And Vomiting: A Review. 4<sup>th</sup> International Conference on the Science of Nutrition in Medicine and Healthcare. 2014; May 3-5. Gold Coast, Australia.
82. **Vitetta L**. The gastrointestinal tract microbiome and the metabolism of herbal compounds such as *trigonella foenum-graecum* extract. The 4<sup>th</sup> International Symposium on Curry and Spice (April 24, 2014) in Seoul, South Korea.
83. **Vitetta L**. Probiotics, the gastrointestinal tract microbiome and musculoskeletal diseases. International Probiotic Association World Congress. May 9-10, 2014, Athens, Greece. In: Beneficial Microbes 5 (Suppl 1): 23.
84. Schloss J, Colosimo M, Airey C, Masci PP, Linnane AW, **Vitetta L**. B complex vitamins reduce the onset and severity of chemotherapy induced sensory peripheral neuropathy. 7<sup>th</sup> International Conference and Exhibition on Nutraceuticals and Functional Foods. October 14-17, 2014, Istanbul, Turkey.
85. Marx W, Ried K, McKavanagh D, **Vitetta L**, Sali S, Isenring L. Ginger as an adjuvant for chemotherapy-induced nausea and vomiting: where does the evidence stand? Asia Pacific Journal of Clinical Oncology 2014;10:115-116.
86. Rao A, Steels E, **Vitetta L**, Inder W, Beccaria G. Influence of a specialized *Trigonella foenum-graecum* seed extract (Libifem), on testosterone, estradiol and sexual function, a randomized placebo-controlled study. 25<sup>th</sup> Annual Meeting of The North American Menopause Society October 15–October 18, 2014, Washington, DC. In: Menopause 21(12):1360-1361.
87. Briskey D, Peake J, Coulson S, **Vitetta L**. High Fat Diet, Probiotics and Non-Alcoholic Fatty Liver Disease 4<sup>th</sup> Beneficial Microbes Conference, The Hague, Netherlands, 2015, 75, P25.
88. Marx W, Ried K, Sali A, **Vitetta L**, McKavanagh D, McCarthy A, Thomson D, Isenring L. Can ginger improve chemotherapy-induced nausea and vomiting related quality of life? The 5<sup>th</sup> Science of Nutrition in Medicine and Healthcare Conference, Melbourne, May 2-3, 2015; 68.
89. Schloss J, Colosimo M, Airey C, Linnane AW, Masci P, Vitetta L. Chemotherapy induced neuropathy (CIPN) and vitamin B12 deficiency. The 5<sup>th</sup> Science of Nutrition in Medicine and Healthcare Conference, Melbourne, May 2-3, 2015; 74.
90. RJ Ellis, DM Small, KL Ng, DA Vesey, **L Vitetta**, R Francis, C Morais, GC Gobe. Indoxyl Sulphate Induces Hypertrophy and Impaired Metabolic Activity In Cultured Human Proximal Tubular Cells. Aust New Zealand Soc of Nephrol (Annual Scientific Meeting) 2015; Sep 7–9. Canberra, Australia.
91. **Vitetta L**. Reactive oxygen species and their lifelong regulation of the metabolome. 6<sup>th</sup> World Congress on Targeting Mitochondria. Oct 28–30, 2015. Berlin, Germany.
92. **Vitetta L**. A multi-strain probiotic preparation in a mouse model of a high fat diet / obesity induced liver steatosis. 5<sup>th</sup> Annual Science of Nutrition in Medicine and Healthcare Conference. May 2-3, 2015. Melbourne, Australia.
93. Palacios T, **Vitetta L**, Coulson S, Butt H, Caterson I. The Effect of a Multi-Strain Probiotic on Metabolic Bio-Markers in Adults with Prediabetes and Recently Diagnosed Type 2 Diabetes Mellitus (T2DM). ICO May 1-4, 2016, Vancouver, Canada.
94. Vitetta L, Palacios T, Coulson S, Caterson ID. The administration of multi-species probiotics that shifts the intestinal microbiome to improve metabolic inflammatory biomarkers in adults with pre-diabetes and type 2 diabetes mellitus (T2DM). RACGP, Perth Oct 2016.
95. Chen T, Ellis R, Morais C, Gobe G, **Vitetta L**. Nephrotoxic effects of cis-diamminedichloroplatinium II (cisplatin) can be ameliorated using Coenzyme Q10 (CoQ10), 7<sup>th</sup> World Congress on Targeting Mitochondria. Oct 24–26, 2016. Berlin, Germany.
96. Palacios T, Caterson I, Madigan C, **Vitetta L**. The Efficacy of A Novel Probiotic on Glucose Metabolism: A Randomised Controlled Trial. The 4<sup>th</sup> Latin American Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension. 16-18 Mar 2017. Buenos Aires, Argentina.
97. **Vitetta L**. The intestinal microbiome, metabolic diseases and probiotics. BIT 15<sup>th</sup> International Conference: IDDST Jul 26-28 2017. Osaka, Japan.
98. **Vitetta L**. Mood disorders cognition and the intestinal mucosa. Australian Society of Lifestyle Medicine 15-17 Sep 2017. Sydney, Australia.

99. Kalma B, [Ellis RJ](#), Vitetta L, Wood ST, Gobe GC. Pilot Study: Urinary Indoxyl Sulphate As A Predictor Of Postoperative Kidney Function Following Radical Tumour Nephrectomy. 54<sup>th</sup> Australian and New Zealand Society of Nephrology. Annual Scientific Meeting 8-12 Sep 2017. Sydney, Australia.
100. Palacios T, **Vitetta L**, Madigan C, Caterson I. The development of a evidence-based probiotic formulation and its efficacy in obesity and type 2 diabetes. 4th Beneficial Microbes Conference, 9-11 Oct 2017. Amsterdam, The Netherlands
101. **Vitetta L**. Cancer Treatments, the Intestinal Microbiome and Probiotics. IPA World Congress | Asia Probiota. 11-13 Oct 2017. Singapore.
102. Palacios T, **Vitetta L**, Madigan C, Caterson I. Prediabetes and Early Diagnosed T2DM: safety tolerability and pilot exploratory study preliminary results. 5th MICROBIOME R And D And BUSINESS COLLABORATION FORUM: USA COLLABORATIONS IN MICROBIOME RESEARCH, LIVE BACTERIAL THERAPEUTICS, HUMAN HEALTH & DISEASE | 2nd PROBIOTICS CONGRESS: USA. 2-3 Nov 2017. San Diego, USA.
103. Thomsen M, **Vitetta L**. Optimising the Gut Microbiome: Adjuvant Treatments/Therapies. Clinical Oncological Society of Australia; Pre-Conference Workshop Nov 12 2017. Sydney, Australia
104. **Vitetta L**, Clarke S, Thomsen M. The intestinal microbiome, chemotherapy and adjuvant treatments with probiotics. Asia-Pacific Journal of Clinical Oncology [Clinical Oncological Society of Australia] 2017; Nov 13-15; 13(4):98, ABS#105. Sydney, Australia.
105. **Vitetta L**. The intestinal microbiome, cancer treatments and adjuvant probiotics. 4th Annual Symposium. Integrative Medicine: The Art and Science. 24-25 Nov 2017. Melbourne, Australia.
106. Palacios T, **Vitetta L**, Coulson S, Madigan CD, Caterson ID. A novel probiotic for glucose management: A randomized double-blind placebo-controlled pilot study. Obesity Research and Clinical Practice 2019;13(1):99-100.
107. Palacios T, **Vitetta L**, Caterson I, Kim JN, Soto-Giron M, Ishoey T, Toledo T, Soto J, Schott EM, Briskey D, Madigan C, Coulson S, Lam Y, Hall S. A randomised controlled pilot study to investigate the effect of a multi-species probiotic formulation and metformin as modulators of the intestinal microbiome for the management of diabetes. Nutrients 2019–In Nutritional Advances in the Prevention and Management of Chronic Disease, Sept 25-27; Barcelona, Spain.
108. **Vitetta L**. Mood Disorders and the Brain–Intestinal Mucosa–Appendix–Microbiome–Brain Loop. Keynote Invitation. Probiota Asia Conference, Singapore, 22-24 Oct 2019.
109. Thomsen M, **Vitetta L**, Clarke S. Intestinal microbiome and chemotherapy-induced neutropenia. Clinical Oncological Society of Australia Scientific Conference, Adelaide, 12-14 Nov 2019.
110. **Vitetta L**, Clarke S, McLachlan AJ, Henson J, Fletcher C, Vitetta G, Rutolo D, Hall S. A Novel Delivery Mechanism for Cannabinoids in Pain Management. Clinical Oncological Society of Australia Scientific Conference, Adelaide, 12-14 Nov 2019.
111. **Vitetta L**. The Brain-Intestinal Mucosa-Appendix-Microbiome-Brain Loop. Australian Pharmaceutical Professional Conference. Gold Coast Convention and Exhibition Centre. 19-22 Mar 2020.
112. **Vitetta L**, Henson HD, Rutolo R, Hall S. An oro-buccal nanoparticle-cannabis delivered medicine for pain management in cancer. 9th Global Nanotechnology Congress and Expo. Miami, Florida, USA. 13-14 Apr 2020.
113. Clarke S, Butcher B, McLachlan AJ, Henson JD, Rutolo D, Hall S, **Vitetta L**. Can improved mucosal absorption allow a THC/CBD oro-buccal spray to achieve clinical efficacy in chronic pain? ANZCA ASM Poster (Anaesthesia and Pain Medicine in Australia and New Zealand) 30<sup>th</sup>Apr- 4<sup>th</sup>May Melbourne 2021.
114. Chen J, **Vitetta L**. Butyrate Sensitizes Epithelioid Mesothelioma Cells to Oxaliplatin. 15<sup>th</sup> Meeting of the International Mesothelioma Interest Group Poster. In section: Mesothelioma Biology and Novel Targets | 306 (iMig 2021) May 7–9, 2021.
115. Sikali JF, Fletcher C, Gillespie A, Hall L, Henson JD, Hall S, **Vitetta L**, and the Medical Science Liaison Team at Medlab Clinical. An Observational Study Investigating And Auditing The Safety, Tolerability And Further Efficacy Characteristics Of A Pharmaceutical Grade Cannabis-Based Medicine Prescribed To Eligible Patients For The Management Of Cancer Related Or Non-Cancer Related Pain In General And Specialty Medical Practices Australia-Wide. 48<sup>th</sup> Annual Scientific Meeting COSA 16-18<sup>th</sup> November, Brisbane 2021.
116. Clarke S, Butcher B, McLachlan AJ, Henson JD, Rutolo D, Hall S, **Vitetta L**. Can improved mucosal absorption allow a THC/CBD oro-buccal spray to achieve clinical efficacy in chronic pain? Australian Pain Society 19-20<sup>th</sup> April 2022, Hobart.
117. Clarke S, Butcher BE, McLachlan AJ, Hendon JD, Rutolo D, Hall S, **Vitetta L**. Can oral administration provide a suitable plasma cannabinoid profile for the effective treatment of chronic pain? IASP World Congress on Pain 19-23 September 2022, Toronto Canada.

---

#### Under Review

- **Vitetta L, Clarke S, Butcher BB, McLachlan AJ, Henson JD, Rutolo D, Hall S. A Pilot Clinical and Pharmacokinetic Study of  $\Delta^9$ -Tetrahydrocannabinol (THC) / Cannabidiol (CBD) Nanoparticle Oro-Buccal Spray in Patients with Advanced Cancer Experiencing Uncontrolled Pain. PainWeek International Conference Las Vegas, US. September 2022.**